Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for severe muscle and cardiac disorders. The company’s current portfolio centers on precision medicine programs designed to address rare neuromuscular diseases and inherited heart conditions, with a platform built around small-molecule approaches that target key muscle proteins and pathways. Its work spans muscular dystrophy and hypertrophic cardiomyopathy research, as well as other disorders where abnormal muscle function plays a central role. Edgewise Therapeutics Inc. operates as a clinical-stage developer of medicines aimed at improving how muscle diseases are treated in specialized medical settings, supporting both neuromuscular and cardiovascular care.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Kevin Koch Ph.D.

Employees

127

Headquarters

Boulder, CO, United States

Website

edgewisetx.com